These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 37858327)

  • 1. Rapidly loading emicizumab without immunosuppression in acquired haemophilia.
    Ragni MV
    Lancet Haematol; 2023 Nov; 10(11):e870-e871. PubMed ID: 37858327
    [No Abstract]   [Full Text] [Related]  

  • 2. Paradigm shifts in haemophilia A therapy with emicizumab prophylaxis in Asia.
    Sosothikul D; Moonla C
    Ann Acad Med Singap; 2023 Nov; 52(11):556-558. PubMed ID: 38920143
    [No Abstract]   [Full Text] [Related]  

  • 3. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors.
    Brophy DF; Martin EJ; Kuhn J
    Haemophilia; 2019 Mar; 25(2):e121-e123. PubMed ID: 30748061
    [No Abstract]   [Full Text] [Related]  

  • 4. Switching to emicizumab: A prospective surveillance study in haemophilia A subjects with inhibitors.
    Dubé E; Merlen C; Bonnefoy A; Pilon J; Zourikian N; Gauthier J; St-Louis J; Rivard GÉ
    Haemophilia; 2023 Jan; 29(1):348-351. PubMed ID: 36315386
    [No Abstract]   [Full Text] [Related]  

  • 5. Laboratory coagulation tests and emicizumab treatment A United Kingdom Haemophilia Centre Doctors' Organisation guideline.
    Jenkins PV; Bowyer A; Burgess C; Gray E; Kitchen S; Murphy P; Platton S; Riddell A; Chowdary P; Lester W
    Haemophilia; 2020 Jan; 26(1):151-155. PubMed ID: 31859415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emicizumab assays evaluations with four different reagents in severe haemophilia A patients: Concentration from baseline to maintenance therapy.
    Launois A; De Raucourt E; Martin-Toutain I; Samdjee F; Le Dore S; Ferre E; Flaujac C
    Haemophilia; 2023 Jan; 29(1):374-376. PubMed ID: 36446748
    [No Abstract]   [Full Text] [Related]  

  • 7. Utilization of emicizumab in the treatment of a case of acquired hemophilia A.
    Ocaña Gómez MÁ; Esquivel Negrín J; Ríos De Paz M; De Dios García MD
    Farm Hosp; 2024; 48(1):45-47. PubMed ID: 37468348
    [No Abstract]   [Full Text] [Related]  

  • 8. [Translated article] Utilization of emicizumab in the treatment of a case of acquired haemophilia A.
    Ocaña Gómez MÁ; Esquivel Negrín J; Ríos De Paz M; De Dios García MD
    Farm Hosp; 2024; 48(1):T45-T47. PubMed ID: 37884400
    [No Abstract]   [Full Text] [Related]  

  • 9. Recurrence of a high-titre factor VIII inhibitor in a haemophilia A patient on emicizumab prophylaxis.
    Doshi BS; Witmer CM
    Haemophilia; 2021 Jul; 27(4):e551-e553. PubMed ID: 33866659
    [No Abstract]   [Full Text] [Related]  

  • 10. A phase IV, multicentre, open-label study of emicizumab prophylaxis in people with haemophilia A with or without FVIII inhibitors undergoing minor surgical procedures.
    Escobar M; Dunn A; Quon D; Trzaskoma B; Lee L; Ko RH; Carpenter SL
    Haemophilia; 2022 Jul; 28(4):e105-e108. PubMed ID: 35510949
    [No Abstract]   [Full Text] [Related]  

  • 11. Prophylaxis with emicizumab in children under 12 years old with haemophilia A without inhibitors in Uruguay: National experience.
    Lemos F; Petraccia C; Fraga ML; Casuriaga AL; Lutz S; Gómez R; Giachetto G; Boggia B
    Haemophilia; 2024 Jul; 30(4):1077-1079. PubMed ID: 38684449
    [No Abstract]   [Full Text] [Related]  

  • 12. Reappearance of inhibitor in a tolerized patient with severe haemophilia A during FVIII-free emicizumab therapy.
    Capdevila L; Borgel D; Lasne D; Lacroix-Desmazes S; Desvages M; Delignat S; Bally C; Frenzel L; Harroche A
    Haemophilia; 2021 Jul; 27(4):e581-e584. PubMed ID: 34004050
    [No Abstract]   [Full Text] [Related]  

  • 13. Factor VIII-Mimetic Function of Humanized Bispecific Antibody in Hemophilia A.
    Shima M; Hanabusa H; Taki M; Matsushita T; Sato T; Fukutake K; Fukazawa N; Yoneyama K; Yoshida H; Nogami K
    N Engl J Med; 2016 May; 374(21):2044-53. PubMed ID: 27223146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of VIII inhibitors beyond 50 exposure days to rFVIII during prophylactic emicizumab therapy.
    Mitani Y; Honda M; Mizushima Y; Mori M; Fukuoka K; Oshima K; Arakawa Y; Taira K; Tanami Y; Koh K
    Haemophilia; 2023 Nov; 29(6):1653-1655. PubMed ID: 37707369
    [No Abstract]   [Full Text] [Related]  

  • 15. Effects of emicizumab on APTT, one-stage and chromogenic assays of factor VIII in artificially spiked plasma and in samples from haemophilia A patients with inhibitors.
    Bowyer A; Kitchen S; Maclean R
    Haemophilia; 2020 May; 26(3):536-542. PubMed ID: 32249990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro evaluation of global coagulation potentials in the co-presence of plasma-derived factors Viia/X products (Byclot
    Nakajima Y; Takami E; Nakano H; Nogami K
    Haemophilia; 2022 Sep; 28(5):e149-e152. PubMed ID: 35947585
    [No Abstract]   [Full Text] [Related]  

  • 17. Blue toe syndrome, severe haemophilia A and emicizumab.
    Cardoso PSR; da Silva CBPG; de Abreu ES; Oliveira AG; Pereira IFM; Navarro TP; Rezende SM
    Haemophilia; 2024 Jan; 30(1):241-244. PubMed ID: 37870891
    [No Abstract]   [Full Text] [Related]  

  • 18. Transplacental transfer of emicizumab: Experience with emicizumab in a pregnant female with severe hemophilia A and an inhibitor.
    Kharel Z; Pruthi RK; Kouides P; Reid R
    Haemophilia; 2024 May; 30(3):868-871. PubMed ID: 38650315
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A.
    Le Quellec S
    Drug Des Devel Ther; 2020; 14():469-481. PubMed ID: 32099331
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world data on emicizumab prophylaxis in the Milan cohort.
    Arcudi S; Gualtierotti R; Marino S; Nicolò G; Biguzzi E; Ciavarella A; Boscarino M; Siboni SM; Schiavone L; Novembrino C; Valsecchi C; Peyvandi F
    Haemophilia; 2022 Sep; 28(5):e141-e144. PubMed ID: 35853212
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.